P831: Acute infusion reactions due to different biologic agents in a large cohort of patients with Inflammatory Bowel Disease.ECCO'24Year: 2024
Authors: Colantuono, S.(1);Caruso, C.(2);Rumi, G.(2);Capobianco, I.(2)*;Blasi, V.(2);Termite, F.(2);Coppola, G.(2);Laterza, L.(2);Lopetuso, L.R.(2);Mignini, I.(2);Napolitano, D.(2);Parisio, L.(3);Pugliese, D.(2);Scaldaferri, F.(2);Gasbarrini, A.(2);Papa, A.(4);
(1)CEMAD- Centro Malattie dell’Apparato Digerente, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;(2)CEMAD - Centro Malattie dell’Apparato Digerente, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;(3)CEMAD - Centro Malattie dell’Apparato Digerente, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy;(4)CEMAD - Centro Malattie dell’Apparato Digerente, Fondazione Policlinico Gemelli- IRCCS- Università Cattolica del S. Cuore, Rome, Italy;
P832: Postoperative fever and CRP levels as predictive markers of postoperative recurrence of Crohn’s disease after ileocolic resectionECCO'24Year: 2024
Authors: Van Tieghem, C.(1)*;Bislenghi, G.(1);Fieuws, S.(2);Wolthuis, A.(1);D@E@Hoore, A.(1);
(1)University Hospitals Leuven, Abdominal Surgery, Leuven, Belgium;(2)KU Leuven, Department of Public Health and Primary Care- Leuven Biostatistics and Statistical Bioinformatics Center, Leuven, Belgium;
P833: Burden of steroid use in patients with moderate ulcerative colitis in Europe and the United StatesECCO'24Year: 2024
Authors: Shah , S.(1);Knight , H.(2);O’Neill , G.(2);Lukanova , R.(2);Davé , K.(3);Rosen , M.(1)*;
(1)Bristol Myers Squibb, n/a, Princeton, United States;(2)Adelphi Real World, Gastroenterology, Bollington, United Kingdom;(3)Bristol-Myers Squibb Pharmaceuticals Ltd, n/a, Uxbridge, United Kingdom;
P834: Choosing wisely: Ustekinumab in Elderly Crohn’s Patients – A Comparative StudyECCO'24Year: 2024
Authors: Dar Antaki, L.(1)*;Shani, U.(1);Dotan, A.(1);Ukashi , O.(1);Ben-Horin, S.(1);Kopylov, U.(1);Levartovsky, A.(1);
(1)Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;
P835: Acceptability, feasibility, and adherence of an emulsifier-free diet in healthy volunteersECCO'24Year: 2024
Authors: Wellens, J.(1,2)*;Luppens, M.(2);Hoekx, S.(1);Vanderstappen, J.(1);Van Elst, L.(2);Vissers, E.(2);Ferrante, M.(1,2);Verstockt, B.(1,2);Verbeke, K.(2);Matthys, C.(3,4);Vermeire, S.(1,2);Sabino, J.(1,2);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)Translational Research Center for Gastrointestinal Disorders TARGID- KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(3)Clinical and Experimental Endocrinology- KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(4)University Hospitals Leuven, Department of Endocrinology, Leuven, Belgium;
P836: Prospective evaluation of the switch from adalimumab originator to different biosimilars in IBD patients : acceptability and persistance at 1 year.ECCO'24Year: 2024
Authors: D’Abbundo, G.(1);Nachury, M.(1);Hambli, S.(1);Desreumaux, P.(1);Gerard, R.(1);Pahul, M.(1);Blondeaux, A.(1);Duveau, N.(2);Wils, P.(1)*;
(1)University Hospital of Lille, Gastroenterology, Lille, France;(2)Victor Provo Hospital of Roubaix, Gastroenterology, Roubaix, France;
P838: Determing factors that influence Vedolizumab Response in Inflammatory Bowel Diseases: A Prospective StudyECCO'24Year: 2024
Authors: Knezevic, T.(1)*;Dobrosavljevic , A.(1);Odanovic, O.(1);Sreckovic , S.(1);Kralj, Đ.(1);Mitrović, M.(1);Svorcan, P.(1,2);Markovic, S.(1,2);
(1)University Hospital Zvezdara, Department of gastroentherology and hepatology, Belgrade, Serbia;(2)Faculty of Medicine, University of Belgrade, Belgrade, Serbia;
P839: Acute interstitial nephritis in patients with Inflammatory Bowel Disease treated with vedolizumab: a systematic reviewECCO'24Year: 2024
Authors: ForssMD PhD, A.(1)*;Flis, P.(2);Sotoodeh, A.(1);Kapraali, M.(3);Rosenborg, S.(4);
(1)Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden;(2)Karolinska Institutet, Department of Laboratory Medicine- Division of Clinical Pharmacology, Stockholm, Sweden;(3)Karolinska University Hospital, Gastroenterology unit Department of Gastroenterology Dermatovenereology and Rheumatology, Stockholm, Sweden;(4)Karolinska University Hospital, Clinical Pharmacology, Stockholm, Sweden;
P840: Structural evaluation of Inflammatory Bowel Disease Comprehensive Care Units in Brazil.ECCO'24Year: 2024
Authors: Quaresma, A.(1)*;Guedes, L.(2);Barros, J.(3);Baima, J.(4);Imbrizi, M.(5);Zeroncio, M.(6);Kotze, P.(7);Flores, C.(8);
(1)UNOESC - Universidade do Oeste de Santa Catarina, Ambulatorio De Coloproctologia, Joaçaba, Brazil;(2)Mater dei, Gastroenterology and endoscopy, Belo Horizonte, Brazil;(3)Cliged Clinic, Nursing, Macaé, Brazil;(4)Nove de Julho University, Medical Science Department, Bauru, Brazil;(5)UNICAMP - University of Campinas, Department of Surgery, Campinas, Brazil;(6)Hospital Geral Promater, Centro de Infusão de Medicação Biológica, Natal, Brazil;(7)PUCPR - Pontifícia Universidade Católica do Paraná, Health Sciences Graduate Program, Curitiba, Brazil;(8)Centro de Doenças Inflamatórias Intestinais do Rio Grande do Sul, Manager, Porto Alegre, Brazil;GEDIIB
P841: Exploring Factors Influencing Rutgeerts Score Changes After Ileocecal Resection in Crohn@E@s Disease PatientsECCO'24Year: 2024
Authors: Siham, B.(1)*;Amri, F.(2);koulali , H.(2);zazour, A.(2);Ismaili, Z.(2);kharrasse, G.(2);
(1)service d@E@hépato-gastro-entérologie, CHU mohamed VI, oujda, Morocco;(2)service d@E@hépato-gastro-entérologie, Chu Mohammed VI, oujda, Morocco;
P842: Assessment of body composition parameters in patients with inflammatory bowel disease treated with biological therapyECCO'24Year: 2024
Authors: Spirić, J.(1)*;Topličanin , A.(1);Vuksanović, S.(1);Nikolić, A.(1);Jovičić, I.(1);Đuranović, S.(1,2);Popović, D.(1,2);Đelić, M.(3);Dragašević, S.(1,2);Sokić Milutinović, A.(1,2);
(1)University Clinical Centre of Serbia, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia;(2)University of Belgrade, School of Medicine, Belgrade, Serbia;(3)University of Belgrade, Institute of Medical Physiology „Rihard Burijan”, Belgrade, Serbia;
P843: Effectiveness and tolerability of methotrexate combined with biologics in patients with Crohn’s disease: A multicenter observational studyECCO'24Year: 2024
Authors: Park, J.(1)*;Jaeyoung, C.(2);Soo Jung , P.(1);Jae Jun , P.(1);Tae Il , K.(1);Hyuk , Y.(3);Jae Hee , C.(1);
(1)1Department of Internal Medicine- 2Institute of Gastroenterology- Severance Hospital- Yonsei University College of Medicine- Seoul- Korea, 1Department of Internal Medicine- 2Institute of Gastroenterology, Seoul, Korea- Republic Of;(2)3Department of Internal Medicine- Gangnam Severance Hospital- Yonsei University College of Medicine- Seoul- Korea, Department of Internal Medicine, Seoul, Korea- Republic Of;(3)4Department of Internal Medicine- Seoul National University Bundang Hospital- Seongnam- Korea, Department of Internal Medicine, Seoul, Korea- Republic Of;
P844: Frequency and effectiveness of dose de-escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDAECCO'24Year: 2024
Authors: Rubín De Célix, C.(1)*;Ricart, E.(2);Martín-Arranz, M.D.(3);de Francisco, R.(4);Barrio, J.(5);Mesonero, F.(6);Gomollón, F.(7);de Castro, L.(8);Ramos, L.(9);García-López, S.(10);Arias, L.(11);Mañosa, M.(12);Iglesias, E.(13);Calvet, X.(14);Pascual, I.(15);Casanova, M.J.(1);Pérez-Calle, J.L.(16);Giordano, A.(17);Sierra, M.(18);Vera, I.(19);Navarro-Llavat, M.(20);Lorente, R.(21);Piqueras, M.(22);Rivero, M.(23);Guardiola, J.(24);Esteve, M.(25);Fuentes Coronel, A.(26);Rodríguez-Lago, I.(27);Ponferrada, Á.(28);Ber, Y.(29);Tardillo, C.(30);Márquez, L.(31);Carpio, D.(32);Taxonera, C.(33);Bermejo, F.(34);Busquets, D.(35);Camps, B.(36);Domènech, E.(12);Chaparro*, M.(1);P. Gisbert*, J.(1);
(1)Gastroenterology Department, Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid UAM- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, Spain;(2)Gastroenterology Department, Hospital Clínic i Provincial- Institut d’Investigacions Biomèdiques August Pi i Sunyer IDIBAPS- and CIBEREHD, Barcelona, Spain;(3)Gastroenterology Department, Hospital Universitario de La Paz, Madrid, Spain;(4)Gastroenterology Department, Hospital Universitario Central de Asturias and ISPA, Asturias, Spain;(5)Gastroenterology Department, Hospital Río Hortega, Valladolid, Spain;(6)Gastroenterology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain;(7)Gastroenterology Department, Hospital Clínico Lozano Blesa- Instituto de investigación sanitaria de Aragón IIS and CIBEREHD, Zaragoza, Spain;(8)Gastroenterology Department, Hospital Álvaro Cunqueiro, Vigo, Spain;(9)Gastroenterology Department, Complejo Hospitalario Universitario de Canarias, La Laguna, Spain;(10)Gastroenterology Department, Hospital Universitario Miguel Servet and IIS, Zaragoza, Spain;(11)Gastroenterology Department, Hospital Universitario de Burgos, Burgos, Spain;(12)Gastroenterology Department, Hospital Universitario Germans Trias i Pujol and CIBEREHD, Badalona, Spain;(13)Gastroenterology Department, Hospital Reina Sofía- IMIBIC and UCO, Córdoba, Spain;(14)Gastroenterology Department, Hospital Universitari Parc Taulí. Institut d@E@Investigació i Innovació Parc Taulí. Departament de Medicina. Universitat Autònoma de Barcelona and CIBEREHD, Barcelona, Spain;(15)Gastroenterology Department, Hospital Clínico de Valencia, Valencia, Spain;(16)Gastroenterology Department, Hospital Universitario de Alcorcón, Madrid, Spain;(17)Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;(18)Gastroenterology Department, Complejo Asistencial Universitario de León, León, Spain;(19)Gastroenterology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain;(20)Gastroenterology Department, Hospital Moisès Broggi, Sant Joan Despí, Spain;(21)Gastroenterology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain;(22)Gastroenterology Department, Consorci Sanitari de Terrassa, Terrassa, Spain;(23)Gastroenterology Department, Hospital Universitario Marqués de Valdecilla and IDIVAL, Santander, Spain;(24)Gastroenterology Department, Hospital Universitari Bellvitge, L@E@Hospitalet de Llobregat, Spain;(25)Gastroenterology Department, Hospital Universitari Mútua Terrassa. University of Barcelona and CIBEREHD, Terrassa, Spain;(26)Gastroenterology Department, Complejo Asistencial de Zamora, Zamora, Spain;(27)Gastroenterology Department, Hospital de Galdakao, Bilbao, Spain;(28)Gastroenterology Department, Hospital Universitario Infanta Leonor, Madrid, Spain;(29)Gastroenterology Department, Hospital de San Jorge, Huesca, Spain;(30)Gastroenterology Department, Hospital Universitario Nuestra Sra. de la Candelaria, Santa Cruz de Tenerife, Spain;(31)Gastroenterology Department, Hospital del Mar and Institut Hospital del Mar d@E@Investigacions Mèdiques IMIM, Barcelona, Spain;(32)Gastroenterology Department, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain;(33)Gastroenterology Department, Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Carlos IdISSC, Madrid, Spain;(34)Gastroenterology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain;(35)Gastroenterology Department, Hospital Dr. Josep Trueta, Girona, Spain;(36)Gastroenterology Department, Hospital General de Granollers, Barcelona, Spain;on behalf of the ENEIDA project of GETECCU *Co-senior authorship
P845: Vedolizumab induces endoscopic healing uniformly irrespective of disease location: post-hoc analysis of the LOVE-CD trialECCO'24Year: 2024
Authors: Hens, B.(1)*;Oldenburg, L.(2);Molnár, T.(3);Baert, F.(4);Clasquin, E.(2);Vermeire, S.(5);Löwenberg, M.(2);D@E@Haens, G.(2);
(1)University Hospital Brussels, Gastroenterology and Hepatology, Jette, Belgium;(2)Amsterdam University Medical Centers, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(3)Albert Szent-Györgyi Medical School, Gastroenterology and Hepatology, Szeged, Hungary;(4)AZ Delta, Gastroenterology and Hepatology, Roeselare, Belgium;(5)University Hospital Leuven, Gastroenterology and Hepatology, Leuven, Belgium;
P846: Impact of 5-ASA discontinuation in children with ulcerative colitis under biological therapyECCO'24Year: 2024
Authors: D@E@Arcangelo, G.(1)*;Di Bari, E.R.(1);Distante, M.(1);Rotulo, S.(1);Brecciaroli, M.(1);Catassi, G.(1);Aloi, M.(1);
(1)Sapienza University of Rome, Department of Pediatrics, Rome, Italy;
P847: Effectiveness of tofacitinib in ulcerative proctitis compared to left sided colitis and pancolitisECCO'24Year: 2024
Authors: SinghD.M., A.(1)*;Mahajan, R.(2);Midha, V.(3);Kaur, K.(4);Singh, D.(5);Bansal, N.(5);Sood, A.(2);
(1)Dayanand Medical College and Hospital- Ludhiana, Department of Gastroenterology, Ludhiana, India;(2)Dayanand Medical College and Hospital, Gastroenterology, Ludhiana, India;(3)Dayanand Medical College and Hospital, Medicine, Ludhiana, India;(4)Dayanand Medical College and Hospital, Pharmacology, Ludhiana, India;(5)Dayanand Medical College and Hospital, Research and Development, Ludhiana, India;
P848: Risankizumab Effectiveness in Ustekinumab-naïve and Ustekinumab-experienced Patients with Crohn’s Disease- Real-world Data from a Large Tertiary CenterECCO'24Year: 2024
Authors: Zinger, A.(1)*;Choi, D.(1);Choi, N.(1);Fear, E.(1);Fine , Z.(1);Cohen, R.D.(1);Dalal, S.D.(1);Krugliak Cleveland, N.(1);Pekow, J.(1);Rubin, D.T.(1);
(1)University of Chicago Medicine, Gastroenterology, chicago, United States;
P849: Bayesian network meta-analysis of the efficacy of advanced therapies for patients with moderately to severely active ulcerative colitis naïve to advanced therapyECCO'24Year: 2024
Authors: Jairath, V.(1)*;Leahy, T.P.(2);Potluri, R.(3);Wosik, K.(4);Gruben, D.(5);Cappelleri, J.C.(5);Bartolome, L.(6);
(1)Western University, Department of Medicine and Department of Epidemiology and Biostatistics, London- ON, Canada;(2)., Putnam Associates- LLC, Toronto- ON, Canada;(3)., Putnam Associates- LLC, New York- NY, United States;(4)., Pfizer Canada, Kirkland- QC, Canada;(5)., Pfizer Inc, Groton- CT, United States;(6)., Pfizer Inc, New York- NY, United States;
P850: Symptomatic effectiveness of ozanimod in routine clinical care of ulcerative colitis: an interim analysis of the multicentre, prospective, noninterventional COLIBRI studyECCO'24Year: 2024
Authors: Schubert, S.(1)*;Stein, J.(2);Efken, P.(3);Helwig, U.(4);Schulze, J.(5);Hellms, T.(6);Jorgensen, E.(7);Poehler, A.M.(8);Scheibner, F.(8);Makki, M.(8);Zeissig, S.(9);
(1)MVZ für Gastroenterologie am Bayerischen Platz, Gastroenterology, Berlin, Germany;(2)CED Studien UG, Gastroenterology, Frankfurt, Germany;(3)Gastroenterologische Gemeinschaftspraxis Minden, Gastroenterology, Minden, Germany;(4)Internistische Praxengemeinschaft Oldenburg, Internal Medicine and Gastroenterology, Oldenburg, Germany;(5)Praxisgemeinschaft Jerichow, Gastroenterology, Jerichow, Germany;(6)Department of Gastroenterology- Hepatology- Infectious Diseases and Endocrinology, Gastroenterology- Hepatology- Infectious Diseases and Endocrinology, Hannover, Germany;(7)Magen-Darm-Zentrum Remscheid, Gastroenterology, Remscheid, Germany;(8)Bristol Myers Squibb, n/a, Munich, Germany;(9)University Medical Center Dresden, Medicine I, Dresden, Germany;
